<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04602702</url>
  </required_header>
  <id_info>
    <org_study_id>SUN-2047</org_study_id>
    <nct_id>NCT04602702</nct_id>
  </id_info>
  <brief_title>Hyper-Personalized Medicine Using Patient Derived Xenografts (PDXovo) for Renal Cell Carcinoma Patients</brief_title>
  <acronym>PDXovo</acronym>
  <official_title>Investigating the Potential of Short-Term Patient Derived Xenografts for Personalized Medicine for Patients With Renal Cell Carcinoma: A Non-Interventional Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sunnybrook Health Sciences Centre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sunnybrook Health Sciences Centre</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Investigators will use novel PDX (patient-derived xenograft) technology to form&#xD;
      xenografts using material from metastatic renal cell carcinoma patients. Xenografts will be&#xD;
      treated with a panel of drugs to determine which agent(s) yield the greatest anti-tumor&#xD;
      effect on the xenograft.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The goal is to use PDXovos, which are chick embryos cultivated in an ex ovo fashion that will&#xD;
      act as a xenograft host, for drug paneling. Chick embryos as a PDX host model system offer&#xD;
      multiple advantages, such as increased tumor take rates, rapid drug testing, a short&#xD;
      evaluation timeframe, and an undeveloped adaptive immune system. Collectively, these&#xD;
      advantages allow for implantation of tumor xenografts, subsequent growth in vivo, subsequent&#xD;
      drug challenge, and subsequent evaluation for anti-tumor effects.&#xD;
&#xD;
      Patients with metastatic forms of renal cell carcinoma (RCC) will be enrolled regardless of&#xD;
      subtype (chromophobe, clear cell, oncocytoma, papillary 1/2, etc.). Metastates will be&#xD;
      provided either via metastasectomy or needle core biopsy of metastatic deposits. Spinal and&#xD;
      intracranial metastases will be included.&#xD;
&#xD;
      Tissue will be processed and briefly cultured in vitro. Upon authentication and expansion to&#xD;
      a suitable number of cells, xenografts will be formed in the chick embryo pre-clinical model.&#xD;
      After implantation (2 days later), drug treatments will be applied topically to each&#xD;
      xenograft's surface. Drug treatments are: sunitinib, pazopanib, axitinib, temsirolimus,&#xD;
      cabozantinib, gemcitabine (N&gt;18/treatment group).&#xD;
&#xD;
      Evaluation of xenografts for anti-tumor effects will be performed via ultrasound imaging&#xD;
      (changes in tumor volume and tumor vascularity) and confirmed by histology (H&amp;E, TUNEL, CD31+&#xD;
      microvessel density). Treatments will be compared to vehicle control (5% DMSO in saline)&#xD;
      treated xenografts. ANOVA (2-way, p&lt;0.01, bon ferroni alpha corrected) analysis will be&#xD;
      performed to identify treatments that lead to the greatest decrease in tumor volume and tumor&#xD;
      vascularity (ultrasound imaging metrics). Agents identified will not be used to intervene in&#xD;
      clinical care. Objective response rates with clinically chosen drug in each patient will be&#xD;
      compared to the corresponding PDX drug panel results using kappa analysis.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 1, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Response</measure>
    <time_frame>3-9 months</time_frame>
    <description>Complete Response, Partial Response</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Stable Disease Response</measure>
    <time_frame>3-9 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Progressive Disease Response</measure>
    <time_frame>3-9 months</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Kidney Neoplasm</condition>
  <condition>Carcinoma, Renal Cell</condition>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      metastasectomy specimens, needle core biopsies&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Odette Cancer Centre Patients (Sunnybrook Hospital)&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Localized kidney cancer inclusion criteria:&#xD;
&#xD;
        i) Age 18+ ii) localized kidney cancer irrespective of subtype undergoing a nephrectomy&#xD;
        (partial/full) iii) Consent to provide tumor tissue for this research&#xD;
&#xD;
        Metastatic kidney cancer inclusion criteria:&#xD;
&#xD;
        i) Age 18+ ii) metastatic kidney cancer irrespective of subtype undergoing a needle biopsy&#xD;
        or resection of lung, liver or brain as part of their routine clinical care.&#xD;
&#xD;
        iii) metastatic cancer irrespective of disease site undergoing a thoracentesis as part of&#xD;
        their routine clinical care.&#xD;
&#xD;
        iv) measurable disease as per RECIST 1.1 criteria v) Consent to provide tumor tissue for&#xD;
        this research&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        â€¢ Inability or unwillingness to provide informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Georg Bjarnason, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sunnybrook Hospital/Odette Cancer Centre</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Elyse Watkins, BSc, PGDip</last_name>
    <role>Study Director</role>
    <affiliation>Sunnybrook Hospital/Odette Cancer Centre</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nir Lipsman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sunnybrook Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hon S Leong, PhD</last_name>
    <phone>416-480-6100</phone>
    <phone_ext>5748</phone_ext>
    <email>hon.leong@sri.utoronto.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sue Santillo</last_name>
    <phone>416-480-6100</phone>
    <phone_ext>3914</phone_ext>
    <email>sue.santillo@sunnybrook.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Odette Cancer Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elyse Watkins, BSc, PGDip</last_name>
      <phone>416-480-6100</phone>
      <phone_ext>84632</phone_ext>
      <email>elyse.watkins@sunnybrook.ca</email>
    </contact>
    <contact_backup>
      <last_name>Hon S Leong, PhD</last_name>
      <phone>416-480-6100</phone>
      <phone_ext>5748</phone_ext>
    </contact_backup>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>September 10, 2020</study_first_submitted>
  <study_first_submitted_qc>October 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 26, 2020</study_first_posted>
  <last_update_submitted>June 30, 2021</last_update_submitted>
  <last_update_submitted_qc>June 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>hyper-personalized medicine</keyword>
  <keyword>patient derived xenograft</keyword>
  <keyword>chick embryo</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
    <mesh_term>Kidney Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

